O-RADS US
- Solid tissue descriptors (papillary projections, solid components, irregular walls/septa) and the color score are the primary drivers of categories 3–5.
- Classic benign lesions (dermoid, endometrioma, hemorrhagic cyst, paraovarian cyst) have dedicated descriptors and are generally O-RADS 2 when <10 cm.
- O-RADS 4 lesions are candidates for problem-solving with O-RADS MRI.
- Applies to the ultrasound lexicon; a separate O-RADS MRI system exists for further characterization after ultrasound.
- 1Confirm an adequate study. If incomplete/technically limited → O-RADS 0.
- 2Is there a true lesion? A physiologic follicle (≤3 cm) or corpus luteum in a premenopausal ovary → O-RADS 1.
- 3Is it a classic benign lesion (simple cyst, hemorrhagic cyst, dermoid, endometrioma, paraovarian cyst) and <10 cm? → O-RADS 2 (management by lesion type + menopausal status).
- 4Otherwise classify by lesion type — unilocular vs multilocular cyst vs lesion with solid tissue — and measure size (10 cm threshold).
- 5Assess solid tissue (papillary projections, solid components, irregular walls/septa) and assign the IOTA color score 1–4 (no / minimal / moderate / marked flow).
- 6Map lesion type + size + solid tissue + color score to the category: unilocular ≥10 cm or smooth multilocular <10 cm (color 1–3) → 3; multilocular ≥10 cm or color 4, multilocular with solid components color 1–2, or a SMOOTH solid lesion color 2–3 → 4; a solid lesion with an IRREGULAR contour (any color score), a smooth solid lesion color 4, a multilocular cyst with solid components color 3–4, or ascites/peritoneal nodularity → 5.
- 7For any branch you cannot resolve confidently, consult the full ACR O-RADS US v2022 table rather than guessing.
Repeat or complete the ultrasound evaluation.
O-RADS 0. Incomplete evaluation; repeat or complete imaging is recommended.
No follow-up.
O-RADS 1. Normal ovary (physiologic finding); no follow-up indicated.
Follow-up depends on lesion type and menopausal status (e.g., simple cyst >5 cm pre-menopausal or >3 cm post-menopausal → follow-up); many require no follow-up.
O-RADS 2 (almost certainly benign, <1% malignancy risk). Management per lesion type and menopausal status.
Management by a gynecologist or gyn-oncologist; ultrasound follow-up or MRI may be considered.
O-RADS 3 (low risk, 1 to <10% malignancy). Management by gynecology; further imaging (MRI) or follow-up may be considered.
Refer to a gynecologic oncologist; consider MRI for further characterization.
O-RADS 4 (intermediate risk, 10 to <50% malignancy). Gynecologic oncology referral; MRI may aid characterization.
Refer to a gynecologic oncologist.
O-RADS 5 (high risk, ≥50% malignancy). Gynecologic oncology referral is recommended.
Sources
- Strachowski LM, et al. O-RADS US v2022: An Update from the American College of Radiology's Ovarian-Adnexal Reporting and Data System US Committee. Radiology. 2023;308(3):e230685.
Educational reference for clinicians — not medical advice. Verify against the primary source before acting on it; guidelines change. Final decisions rest with the interpreting physician and your institution's protocols.